journal article·2024-08Open access

Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma

Xin Peng, Xin Huang, Shaolu Zhang, Naixin Zhang, Shengfan Huang, Yingying Wang, Zhenxing Zhong, Shan Zhu, Haiwang Gao, Zixiang Yu, Xiaotong Yan, Zhennan Tao, Yuxiang Dai, Zhe Zhang, Xi Chen, Feng Wang, Francois X. Claret, Moshe Elkabets, Ning Ji, Yuxu Zhong, Dexin Kong

Advanced Science· Volume 11· Issue 30

Abstract

Abstract PARP inhibitors (PARPi) hold substantial promise in treating glioblastoma (GBM). However, the adverse effects have restricted their broad application. Through unbiased transcriptomic and proteomic sequencing, it is discovered that the BET inhibitor (BETi) Birabresib profoundly alters the processes of DNA replication and cell cycle progression in GBM cells, beyond the previously reported impact of BET inhibition on homologous recombination repair. Through in vitro experiments using established GBM cell lines and patient‐derived primary GBM cells, as well as in vivo orthotopic transplantation tumor experiments in zebrafish and nude mice, it is demonstrated that the concurrent administration of PARPi and BETi can synergistically inhibit GBM. Intriguingly, it is observed that DNA damage lingers after discontinuation of PARPi monotherapy, implying that sequential administration of PARPi followed by BETi can maintain antitumor efficacy while reducing toxicity. In GBM cells with elevated baseline replication stress, the sequential regimen exhibits comparable efficacy to concurrent treatment, protecting normal glial cells with lower baseline replication stress from DNA toxicity and subsequent death. This study provides compelling preclinical evidence supporting the development of innovative drug administration strategies focusing on PARPi for GBM therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: PARP inhibition in cancer therapy · Protein Degradation and Inhibitors · CRISPR and Genetic Engineering

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Key Laboratory of Technologies Enabling Development of Clinical Therapeutics and Diagnostics School of Pharmacy Tianjin Medical University Tianjin 300070 China

Key Laboratory of Immune Microenvironment and Diseases (Ministry of Education) International Joint Laboratory of Ocular Diseases (Ministry of Education) Tianjin Medical University Tianjin 300070 China

Department of Systems Biology the University of Texas MD Anderson Cancer Center Houston TX 77030 USA

State Key Laboratory of Toxicology and Medical Countermeasures Beijing Institute of Pharmacology and Toxicology Beijing 100850 China

Department of Neurosurgery the Affiliated Drum Tower Hospital School of Medicine Nanjing University Nanjing 210008 China

Tianjin Key Laboratory of Ophthalmology and Visual Science Tianjin Eye Institute Tianjin Eye Hospital Tianjin 300020 China

State Key Laboratory of Medicinal Chemical Biology Nankai University Tianjin 300071 China

Department of Genetics School of Basic Medical Sciences Tianjin Medical University Tianjin 300070 China

The Shraga Segal Department of Microbiology Immunology and Genetics Faculty of Health Sciences Ben‐Gurion University of the Negev Beer‐Sheva 84105 Israel

National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital Tianjin 300060 China

Department of Pharmacy Tianjin Medical University General Hospital Tianjin 300052 China

Funding

National Natural Science Foundation of China · Tianjin Medical University

References (82)

Show source-provided references
1. 10.1016/S1470-2045(09)70025-710.1016/S1470-2045(09)70025-7 ↗
2. 10.1001/jama.2017.1871810.1001/jama.2017.18718 ↗
3. 10.1200/JCO.2013.49.696810.1200/JCO.2013.49.6968 ↗
4. 10.1186/s13059-020-02085-110.1186/s13059-020-02085-1 ↗
5. 10.1073/pnas.121974711010.1073/pnas.1219747110 ↗
6. 10.1093/neuonc/now23110.1093/neuonc/now231 ↗
7. 10.1016/j.ccell.2023.02.01910.1016/j.ccell.2023.02.019 ↗
8. 10.1056/NEJMoa130857310.1056/NEJMoa1308573 ↗
9. 10.1016/S1470-2045(18)30675-210.1016/S1470-2045(18)30675-2 ↗
10. 10.1038/s41467-020-17512-x10.1038/s41467-020-17512-x ↗
11. 10.3322/caac.2161310.3322/caac.21613 ↗
12. 10.1038/s41586-023-06623-210.1038/s41586-023-06623-2 ↗
13. 10.1126/scitranslmed.aax410010.1126/scitranslmed.aax4100 ↗
14. 10.1002/advs.20190297110.1002/advs.201902971 ↗
15. 10.1038/s41467-019-10993-510.1038/s41467-019-10993-5 ↗
16. 10.1126/scitranslmed.adf228110.1126/scitranslmed.adf2281 ↗
17. 10.1158/0008-5472.CAN-21-386810.1158/0008-5472.CAN-21-3868 ↗
18. 10.1158/1078-0432.CCR-22-397110.1158/1078-0432.CCR-22-3971 ↗
19. 10.1038/356356a010.1038/356356a0 ↗
20. 10.1038/nrm.2017.5310.1038/nrm.2017.53 ↗
21. 10.1038/s41586-018-0261-510.1038/s41586-018-0261-5 ↗
22. 10.1126/sciadv.abq041410.1126/sciadv.abq0414 ↗
23. 10.1158/0008-5472.CAN-12-275310.1158/0008-5472.CAN-12-2753 ↗
24. 10.1093/emboj/17.18.549710.1093/emboj/17.18.5497 ↗
25. 10.1038/s41586-021-03776-w10.1038/s41586-021-03776-w ↗
26. 10.1038/s41573-020-0076-610.1038/s41573-020-0076-6 ↗
27. 10.1016/j.molcel.2021.06.01110.1016/j.molcel.2021.06.011 ↗
28. 10.1158/2159-8290.CD-17-060510.1158/2159-8290.CD-17-0605 ↗
29. 10.1038/nature1650810.1038/nature16508 ↗
30. 10.1158/0008-5472.CAN-16-055910.1158/0008-5472.CAN-16-0559 ↗
31. 10.1016/j.molcel.2020.04.02710.1016/j.molcel.2020.04.027 ↗
32. 10.1073/pnas.110819010810.1073/pnas.1108190108 ↗
33. 10.1073/pnas.171236311510.1073/pnas.1712363115 ↗
34. 10.1093/annonc/mdx15710.1093/annonc/mdx157 ↗
35. 10.1016/j.pharmthera.2020.10772110.1016/j.pharmthera.2020.107721 ↗
36. 10.1016/j.ccell.2018.01.01910.1016/j.ccell.2018.01.019 ↗
37. 10.1126/scitranslmed.aal164510.1126/scitranslmed.aal1645 ↗
38. 10.1073/pnas.230453412010.1073/pnas.2304534120 ↗
39. 10.1016/j.ebiom.2019.05.03510.1016/j.ebiom.2019.05.035 ↗
40. 10.1158/2159-8290.CD-15-133510.1158/2159-8290.CD-15-1335 ↗
41. 10.1038/s41416-021-01321-010.1038/s41416-021-01321-0 ↗
42. 10.1093/neuonc/noac26310.1093/neuonc/noac263 ↗
43. 10.1158/1535-7163.TARG-13-C24410.1158/1535-7163.TARG-13-C244 ↗
44. 10.1002/advs.20220552910.1002/advs.202205529 ↗
45. 10.1038/s41392-023-01324-810.1038/s41392-023-01324-8 ↗
46. 10.1074/jbc.TM118.00037210.1074/jbc.TM118.000372 ↗
47. 10.1038/nrm200810.1038/nrm2008 ↗
48. 10.1016/j.cell.2012.03.03110.1016/j.cell.2012.03.031 ↗
49. 10.1158/1078-0432.CCR-16-267710.1158/1078-0432.CCR-16-2677 ↗
50. 10.1158/1078-0432.CCR-22-087510.1158/1078-0432.CCR-22-0875 ↗
51. 10.1038/s41389-021-00329-810.1038/s41389-021-00329-8 ↗
52. 10.1093/annonc/mdu44410.1093/annonc/mdu444 ↗
53. 10.1093/jnci/djv21610.1093/jnci/djv216 ↗
54. 10.1038/nature0344310.1038/nature03443 ↗
55. 10.1038/nature0344510.1038/nature03445 ↗
56. 10.1126/science.aam734410.1126/science.aam7344 ↗
57. 10.1056/NEJMoa090021210.1056/NEJMoa0900212 ↗
58. 10.1016/S0140-6736(10)60892-610.1016/S0140-6736(10)60892-6 ↗
59. 10.1158/1078-0432.CCR-13-228710.1158/1078-0432.CCR-13-2287 ↗
60. 10.1016/S1470-2045(17)30469-210.1016/S1470-2045(17)30469-2 ↗
61. 10.1200/JCO.2014.56.272810.1200/JCO.2014.56.2728 ↗
62. 10.1038/nature1193510.1038/nature11935 ↗
63. 10.1186/s13059-016-1042-910.1186/s13059-016-1042-9 ↗
64. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
65. 10.1146/annurev-pathol-012414-04042410.1146/annurev-pathol-012414-040424 ↗
66. 10.1073/pnas.210842111810.1073/pnas.2108421118 ↗
67. 10.1038/ncomms1308710.1038/ncomms13087 ↗
68. 10.1016/j.molcel.2023.07.02610.1016/j.molcel.2023.07.026 ↗
69. 10.1016/j.chembiol.2013.04.00710.1016/j.chembiol.2013.04.007 ↗
70. 10.1038/nature1076010.1038/nature10760 ↗
71. 10.1038/s41580-021-00404-310.1038/s41580-021-00404-3 ↗
72. 10.1038/nsmb131310.1038/nsmb1313 ↗
73. 10.1016/j.molcel.2011.02.00610.1016/j.molcel.2011.02.006 ↗
74. 10.1038/srep2707110.1038/srep27071 ↗
75. 10.1172/JCI12339610.1172/JCI123396 ↗
76. 10.1096/fj.201800183R10.1096/fj.201800183R ↗
77. 10.1016/j.ccell.2018.03.02610.1016/j.ccell.2018.03.026 ↗
78. 10.1016/j.cell.2018.03.02710.1016/j.cell.2018.03.027 ↗
79. 10.1038/s41419-021-03805-610.1038/s41419-021-03805-6 ↗
80. 10.1038/onc.2010.34510.1038/onc.2010.345 ↗
81. 10.1083/jcb.140.6.128510.1083/jcb.140.6.1285 ↗
82. 10.1186/s13046-021-02176-210.1186/s13046-021-02176-2 ↗